Document Detail


Correlation of serum progestagen-associated endometrial protein levels with endometrial biopsies serum steroid levels and therapy for luteal phase defects.
MedLine Citation:
PMID:  1918299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The progestagen-associated endometrial protein (PEP) level rises from the early to the late luteal phase. A study was performed in infertile women where late luteal phase endometrial biopsies and serum PEP levels were obtained. The objective of the study was to evaluate the correlation between the PEP levels and the endometrial biopsies and to determine if subnormal PEP levels could be improved by the same therapies used to correct endometrial defects. There was a poor correlation between PEP levels and endometrial biopsies (r = 0.17). Similarly, there was no significant correlation between PEP levels and levels of the following hormones: mid- and late-luteal phase progesterone (P) (r = 0.186 and 0.282 respectively), mid-luteal phase 17-hydroxyprogesterone (17-OHP) (r = 0.139) and mid-luteal phase oestradiol (r = 0.135). Furthermore, there was no correlation between PEP levels and the dosage of progesterone used in therapy (r = 0.07). There were no statistically significant differences in PEP values (U/ml) depending on whether any fertility drug was taken. Thus our data suggest that progesterone may only have a permissive role, with some other factor(s) controlling the actual rise and fall of PEP.
Authors:
J H Check; K Nowroozi; M L Check; B Vetter
Related Documents :
633209 - Effect of fetal hypophysectomy on the initiation of parturition in the goat.
24693379 - Comparison of maternal serum magnesium level in pre-eclampsia and normal pregnant women.
21278499 - Intrauterine resuscitation during labor.
19747959 - Progesterone regulation of primordial follicle assembly in bovine fetal ovaries.
24937399 - Relationship between anthropometric and haematological parameters among third trimester...
21462299 - No association between maternal pre-pregnancy obesity and risk of hypospadias or crypto...
16429419 - Pattern of maternal serum corticotropin-releasing hormone concentration during pregnanc...
24527849 - Normal outcome of pregnancy with ongoing treatment with natalizumab.
9845399 - Foetal outcome in women with inflammatory bowel disease treated during pregnancy with o...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  6     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  1991 Apr 
Date Detail:
Created Date:  1991-11-08     Completed Date:  1991-11-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  511-4     Citation Subset:  IM    
Affiliation:
University of Medicine and Dentistry of New Jersey, Robert Wood Johnston Medical School, Camden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
17-alpha-Hydroxyprogesterone
Biopsy
Bromocriptine / pharmacology
Clomiphene / pharmacology
Dose-Response Relationship, Drug
Estradiol / blood
Female
Glycoproteins*
Humans
Hydroxyprogesterones / blood
Infertility, Female* / drug therapy,  metabolism,  pathology
Luteal Phase / physiology*
Menotropins / pharmacology
Pregnancy Proteins / blood*
Progesterone / blood,  pharmacology
Radioimmunoassay
Chemical
Reg. No./Substance:
0/Glycoproteins; 0/Hydroxyprogesterones; 0/PAEP protein, human; 0/Pregnancy Proteins; 25614-03-3/Bromocriptine; 50-28-2/Estradiol; 57-83-0/Progesterone; 61489-71-2/Menotropins; 68-96-2/17-alpha-Hydroxyprogesterone; 911-45-5/Clomiphene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation sy...
Next Document:  Comparison of a rapid, quantitative and automated assay for urinary luteinizing hormone (LH), with a...